8-K: Theriva Biologics Advances Oncology Pipeline, Licenses SYN-020

Theriva Biologics reported full-year 2025 financial results, highlighting progress in its VCN-01 oncology program and the licensing of SYN-020, extending its cash runway into Q1 2027.

Summary

• Full-year 2025 financial results were reported, detailing operational highlights and financial performance.
• The company is advancing the clinical development of VCN-01 for pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma.
• SYN-020 was licensed to Rasayana Therapeutics, with potential milestones up to $38 million plus royalties on commercial sales.
• Cash and cash equivalents totaled $13.1 million as of December 31, 2025.
• Recent capital raises increased cash to $15.2 million as of February 26, 2026, providing a cash runway into Q1 2027.
• General and administrative expenses increased by 109% to $15.4 million for the year ended December 31, 2025, from $7.4 million in 2024, primarily due to a $9.0 million contingent consideration adjustment.
• Research and development expenses decreased by 28% to $8.6 million for the year ended December 31, 2025, from $12.0 million in 2024, mainly due to the completion of the VIRAGE Phase 2b clinical trial.
• Net loss was $(23.7) million for the year ended December 31, 2025, compared to $(25.6) million for 2024.
• The audited financial statements for 2025 include an audit opinion with an explanatory paragraph related to the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While there is positive clinical and strategic progress with VCN-01 and the SYN-020 licensing, the significant increase in G&A expenses and the going concern warning from auditors temper the overall sentiment.

Positives

• Received positive scientific advice from the EMA on the design of a Phase 3 trial for VCN-01 in metastatic PDAC, including agreement on sample size, repeated dosing, and adaptive design.
• VCN-01 has received Orphan Drug and Rare Pediatric Disease designation for retinoblastoma.
• Successfully licensed SYN-020 to Rasayana Therapeutics, securing a $300,000 upfront payment and eligibility for up to $16 million in development and regulatory milestones, tiered single-digit royalties, and up to $22 million in sales milestones.
• SYN-020 was well tolerated in Phase 1 clinical studies and is now poised to enter Phase 2 clinical testing.
• Rasayana Therapeutics will assume responsibility and costs for future clinical development and commercialization of SYN-020.
• Cash runway extended into Q1 2027 due to recent capital raises, providing financial stability for the near term.
• Net loss decreased from $(25.6) million in 2024 to $(23.7) million in 2025.
• Research and development expenses decreased by 28% in 2025, reflecting completion of key clinical trials and strategic focus.

Negatives

• General and administrative expenses increased significantly by 109% to $15.4 million in 2025, largely due to a $9.0 million contingent consideration adjustment.
• The audit opinion for the year ended December 31, 2025, includes an explanatory paragraph related to the company's ability to continue as a going concern.
• The company continues to operate at a net loss, reporting $(23.7) million for 2025.

Risks

• Product candidates, including VCN-01 and VCN-12, may not demonstrate safety and effectiveness in clinical indications or produce results consistent with prior data.
• The ability to confirm VCN-12 preclinical data in a clinical setting is uncertain.
• The company may not reach clinical milestones as anticipated, including enrolling the expected number of patients in trials.
• There is a risk that clinical trials may not be completed on time or achieve the desired results and benefits.
• The company may face challenges in obtaining regulatory approval for commercialization of product candidates or complying with ongoing regulatory requirements.
• Regulatory limitations may restrict the company's ability to promote or commercialize its product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing, or sale of products are not guaranteed.
• Developments by competitors could render the company's products obsolete or non-competitive.
• The company's ability to maintain license agreements is a risk.
• The continued maintenance and growth of the company's patent estate is crucial.
• The company's ability to continue to remain well financed is a significant risk, as highlighted by the going concern warning.
• The company's ability to continue as a going concern is dependent on its ability to obtain additional financing and achieve profitable operations.

Future Outlook

The company plans an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the design of a multinational pivotal Phase 3 trial for VCN-01 in PDAC. Additional interactions with the FDA and EMA are planned for 2026 to refine the design of a potential Phase 2/3 trial for VCN-01 in retinoblastoma. Research and development expenses are anticipated to decrease in 2026 due to a workforce reduction plan, the completion of the VIRAGE Phase 2b trial, and Rasayana Therapeutics assuming SYN-020 R&D costs. The company expects its current cash to fund operations into the first quarter of 2027.

Management Comments

• "We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio while we remain focused on the advancement of our oncology pipeline."
• "We continue to advance our lead oncolytic virus candidate VCN-01 towards pivotal clinical development in multiple indications of high unmet need."
• "With the recent feedback from the EMA, we have further clarity on dosing regimen, protocol and overall design for our proposed Phase 3 trial in pancreatic ductal adenocarcinoma (PDAC)."
• "An End-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to finalize our design for a multinational pivotal Phase 3 trial in PDAC, aiming to provide patients with a novel therapy for this difficult to treat solid tumor that has a high mortality rate."
• "Additional interactions with the FDA and EMA are planned for 2026 to refine the design of a potential Phase 2/3 trial for retinoblastoma, for which VCN-01 has received Orphan Drug and Rare Pediatric Disease designation."
• "We continue to engage in potential partnership discussions for the additional innovative drug candidates in our portfolio."

Industry Context

StockSavvy.ai notes that the licensing of SYN-020 to Rasayana Therapeutics reflects a strategic move by Theriva Biologics to monetize non-core assets and focus resources on its lead oncology pipeline, VCN-01. This strategy is common among clinical-stage biotechs seeking to extend cash runways and de-risk development by offloading programs that require significant investment but are not central to their primary focus. The progress with VCN-01 in PDAC and retinoblastoma, particularly the positive EMA feedback and planned FDA meeting, positions Theriva in competitive oncology fields, where novel therapies for high unmet needs like PDAC are highly sought after.

Comparison to Industry Standards

• The company's strategy of licensing out non-core assets like SYN-020 to focus on a lead candidate (VCN-01) is a common industry practice for clinical-stage biotechs to manage capital and pipeline risk. For example, smaller biotechs often partner with larger pharmaceutical companies for late-stage development and commercialization to leverage their resources and expertise, similar to how Rasayana Therapeutics will assume SYN-020's future development costs.
• The receipt of Orphan Drug and Rare Pediatric Disease designations for VCN-01 in retinoblastoma aligns with industry incentives for developing treatments for rare diseases, which often include extended market exclusivity and tax credits, similar to designations received by companies like BioMarin Pharmaceutical for rare disease therapies.
• The "going concern" explanatory paragraph in the audit opinion is a significant red flag, indicating auditor concern about the company's ability to meet its financial obligations over the next year. This is a common issue for early-stage biotechs that are pre-revenue and heavily reliant on capital raises, but it still signals a higher risk profile compared to more established, revenue-generating pharmaceutical companies.

Stakeholder Impact

• Shareholders face potential for value creation from VCN-01's clinical progress and the SYN-020 licensing deal, but also dilution risk from future capital raises and uncertainty from the going concern warning.
• Employees were impacted by a workforce reduction plan implemented on September 30, 2025, indicating job losses.
• Customers/Patients may benefit from potential novel therapies for difficult-to-treat cancers (PDAC, retinoblastoma) if VCN-01 development is successful.
• Creditors face increased risk regarding the company's ability to meet its financial obligations, as indicated by the "going concern" warning.
• Partners, specifically Rasayana Therapeutics, benefit from an exclusive worldwide license for SYN-020, assuming development and commercialization costs.

Next Steps

• Conduct an End-of-Phase 2 meeting with the FDA in 1H 2026 to finalize Phase 3 trial design for VCN-01 in PDAC.
• Engage in additional interactions with the FDA and EMA in 2026 to refine Phase 2/3 trial design for VCN-01 in retinoblastoma.
• Present additional analysis from the VIRAGE Phase 2b study at the American Association of Cancer Research (AACR) meeting from April 17-22, 2026.
• Potentially initiate a Phase 2a study evaluating VCN-01 dosing frequency.
• Undertake exploratory VCN-01 manufacturing scale-up activities.
• Continue preclinical studies supporting VCN-01 and VCN-12.
• Rasayana Therapeutics will assume responsibility and costs for future clinical development and commercialization of SYN-020.
• Continue to engage in potential partnership discussions for additional innovative drug candidates in the portfolio.

Key Dates

Recommendation

While the company shows promising clinical progress with VCN-01 and a strategic licensing deal for SYN-020, the significant increase in G&A expenses and the explicit "going concern" warning from auditors introduce substantial financial uncertainty. The extended cash runway into Q1 2027 provides some breathing room, but future capital raises are likely, posing dilution risk. Investors should hold to monitor the outcomes of the planned FDA and EMA meetings for VCN-01 and the company's ability to secure further financing without excessive dilution.

Keywords

Theriva Biologics, TOVX, VCN-01, Pancreatic Ductal Adenocarcinoma, PDAC, Retinoblastoma, Oncolytic Virus, SYN-020, Rasayana Therapeutics, Biotechnology, Oncology, Clinical-stage, SEC Filing, Financial Results, Cash Runway, Going Concern